Keywords: allergic reaction; antitumor response; antitumor response toxic epidermal necrolysis; BRAF inhibitor; BRAF inhibitor Stevens-Johnson syndrome; BRAF inhibitor toxic epidermal necrolysis; coBRIM allergic reaction; coBRIM adverse effect; coBRIM hypersensitiv
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Melanoma; Nanotechnology; Nanoparticles; Chemotherapy; Immunotherapy; Drug resistance; Vemurafenib; Dabrafenib; Ipilimumab;
Keywords: AKT inhibitor; autoimmune adverse effects; autoimmune dermopathies; B-RAF; dabrafenib; dermatitis; dual inhibitor; dysgeusia; everolimus; hair loss; hedgehog signaling pathway; immunotherapy; immune-related toxicities; ipilimumab; keratoacanthoma; keratos
Keywords: Melanoma; Brain metastases; Vemurafenib; Dabrafenib; BRAF; Ipilimumab; Blood brain barrier;
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
Keywords: Low grade serous ovarian cancer; BRAF mutation; Dabrafenib; Trametinib;
UveÃtis y desprendimiento seroso de retina secundarios al tratamiento sistémico con dabrafenib y trametinib
Keywords: Dabrafenib; Trametinib; PanuveÃtis; Desprendimiento seroso de retina; Melanoma; Inhibidores MAPK; Dabrafenib; Trametinib; Panuveitis; Serous retinal detachment; Melanoma; MAPK inhibitors;
Actinomycose révélée par une ulcération du palais et de la gencive
Keywords: Actinomycose; Ulcération du palais; Ulcération de la gencive; Dabrafenib; Inhibiteur de BRAF; Actinomycosis; Palate ulceration; Gingiva ulceration; Dabrafenib;
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Keywords: Melanoma; Chemotherapy; Vemurafenib; Dabrafenib; Trametinib; Metastatic; Unresectable; BRAF inhibitor; MEK inhibitor; Progression free survival (PFS); Median progression free survival;
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Keywords: Non-small cell lung cancer (NSCLC); BRAF mutations; Mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway; Vemurafenib; Dabrafenib; Trametinib;
Current PerspectiveThe 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
Keywords: Melanoma; Adjuvant therapy; Randomised trials; Nivolumab; Ipilimumab; Dabrafenib; Trametinib;
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome
Keywords: Dabrafenib; melanoma; trametinib; podocyte injury; glomerulopathy; nephrotic syndrome; BRAF inhibitor; MEK inhibitor; targeted cancer therapy; BRAF signaling pathway; proteinuria; PLCε1; renal biopsy; nephrotoxicity; case report;
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes
Keywords: Antagonism; AKT; BRAF; Dabrafenib; Sorafenib;
(Neo)adjuvant systemic therapy for melanoma
Keywords: Cutaneous melanoma; High risk melanoma; Melanoma; Adjuvant; Neoadjuvant; Immunotherapy; Anti CTLA-4; Ipilimumab; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK inhibitor; Trametinib; Cobimetinib; Anti PD1; T-VEC; Tamilogene Laherparepvec; Review;
Original ResearchThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Keywords: Dabrafenib; Trametinib; Vemurafenib; Melanoma; Multivariate analysis;
Antiseptic effects of dabrafenib on TGFBIp-induced septic responses
Keywords: Dabrafenib; TGFBIp; Inflammation; Sepsis;
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
Keywords: BRAFi; BRAF inhibitors; MEKi; MEK inhibitors; Cmin; Trough concentration; CV; Coefficient of variation; EMA; European Medical Agency; ESI; Electrospray ionization; LC-UV; Liquid chromatography combined to UV detection; LLOQ; Low limit of quantification; M
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption
Keywords: Dabrafenib; Polyphosphate; Inflammation; Barrier integrity
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review
Keywords: Melanoma; Brain metastases; Vemurafenib; Dabrafenib; Ipilimumab; Survival;
Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib to Allow Complete Surgical Resection in Patients With BRAF Mutated
Keywords: Dabrafenib; Locally advanced; Melanoma; Neo-adjuvant; Surgery; Trametinib;
Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti-BRAF V600 Inhibitors
Keywords: Dabrafenib; Ivermectin; MAPK; PAK1; Vemurafenib;
Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry
Keywords: Dabrafenib; Trametinib; Therapeutic drug monitoring; Pharmacokinetics; HPLC-MS/MS;
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Keywords: Lung cancer; Targeted therapy; BRAF; Vemurafenib; Dabrafenib;
BRAF inhibitor therapy in HCL
Keywords: Hairy cell leukemia; BRAF V600E; BRAF inhibitor; Vemurafenib; Dabrafenib; MEK;
BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer
Keywords: BRAF; V600E; MEK; Vemurafenib; Dabrafenib; Trametinib; Non-small-cell lung cancer;
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Keywords: Melanoma; Protein kinase inhibitors; Molecular targeted therapy; Proto-oncogene proteins B-raf; Dabrafenib; Trametinib;
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Keywords: BRAF; Vemurafenib; Dabrafenib; Resistance; Acquired; MAPK; NRAS; Splice; MEK1; Meta-analysis
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Keywords: Melanoma; BRAF; MEK; Vemurafenib; Dabrafenib; Trametinib
Les nouveaux médicaments de la cancérologie
Keywords: afatinib; axitinib; cancérologie; dabrafénib; enzalutamide; mébutate d’ingénol; pazopanibafatinib; axitinib; dabrafenib; enzalutamide; ingenol mebutate; oncology; pazopanib
18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
Keywords: BRAF inhibitor; BRAF-mutant; Dabrafenib; FDG-PET; Heterogeneity; Metastatic melanoma;
BRAF inhibitor activity in V600R metastatic melanoma
Keywords: Metastatic melanoma; V600E; V600R; BRAF inhibitor; Vemurafenib; Dabrafenib
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors
Keywords: dabrafenib; food effects; particle size; bioavailability; HPMC; gelatin; capsules; supersaturation; dissolution; clinical pharmacokinetics
Effets indésirables cutanés des inhibiteurs de BRAFÂ : revue systématique
Keywords: Vemurafenib; Dabrafenib; BRAF; Mélanome; Effets indésirables cutanés; Vemurafenib; Dabrafenib; BRAF; Malignant melanoma; Dermatologic adverse events;